Chad M. Salisbury, MBA
Project Farma
Senior Vice President
Chad Salisbury joined Project Farma in October 2022 as Senior Vice President. Chad has over 20 years of experience encompassing gene therapy, vaccines, sterile injectables and small molecules, including the delivery of ~$2B USD of greenfield cGMP manufacturing facilities. Chad has held increasingly responsible management positions in manufacturing, quality, engineering and supply chain.
Chad was most recently VP, Manufacturing at Affinia Therapeutics, a company singularly focused on using innovations in gene therapy to lead the fight against devastating rare and prevalent diseases. Prior to Affinia, Chad held progressive roles at CSL Seqirus, Novartis and Eli Lilly in both the US and Europe.
Chad holds an MBA from Purdue University, an MEM from Duke University and a B.A. from Alfred University.
Chad was most recently VP, Manufacturing at Affinia Therapeutics, a company singularly focused on using innovations in gene therapy to lead the fight against devastating rare and prevalent diseases. Prior to Affinia, Chad held progressive roles at CSL Seqirus, Novartis and Eli Lilly in both the US and Europe.
Chad holds an MBA from Purdue University, an MEM from Duke University and a B.A. from Alfred University.